Agenda for Day 2 – Wednesday, March 24, 2027 - ET (Eastern Time, GMT-05:00)
Move past traditional "why we should collaborate" discussions to explore how patient advocacy organizations and manufacturers can build measurable, value-driven partnerships using a structured approach that demonstrates real-world impact and organizational value
Examine practical applications of the Framework to establish meaningful KPIs, assess advocacy readiness and capability and create evidence-based strategies that resonate with both patient communities and internal stakeholders across therapeutic areas
Explore case studies of patient advocacy organizations and manufacturers who have successfully implemented the IMPACT™ Framework to co-create value, generate actionable data and insights and build sustainable collaborations that inform future strategic decision-making
Leave with concrete approaches to assess your current advocacy partnerships, identify gaps in measurement and impact, and develop a roadmap for elevating engagement maturity within your organization
- Jaye Bea Smalley - Executive Director, Patient Advocacy, Kyverna Therapeutics
- Kari Rosbeck - President & CEO, TSC Alliance
- Examine the growing trend of conducting early-phase clinical work in China and bringing data back to the US. Understand whether China now meets US regulatory standards and what FDA acceptance looks like for China-sourced data
Review a comprehensive analysis of the regulatory and policy environment surrounding China-US biotech collaboration, including recent restrictions, compliance requirements and areas where collaboration remains viable
Break down China's regulatory reforms and accelerated approval pathways for rare diseases
Evaluate the competitive dynamics, influences and opportunities presented by China's growing role in rare disease development, including implications for innovation, intellectual property and strategic competitor partnerships
Examine how the Inflation Reduction Act (IRA) and Most Favored Nation (MFN) policies and international reference pricing are fundamentally reshaping US market access strategies, payer negotiations and US pricing potential for rare disease products
Analyze how global pricing dynamics and policy changes in key international markets are directly impacting US payer coverage decisions, formulary positioning and reimbursement strategies
Explore how current and proposed tariffs are affecting US-based companies' global footprint decisions, including whether to expand internationally or consolidate resources domestically to protect US market positioning
- Learn how to move beyond transactional partnerships to engage patient advocacy organizations as collaborators in evidence generation and strategic planning
- Understand how using patient journeys and advocacy-led registries can be valuable to explore treatment-use trends, gaps in care and patient priorities that may not be fully reflected in claims data
- Explore how to bring together patient-reported experiences, registry findings and healthcare utilization data to develop a more complete value story
- Discover how to translate patient insights into questions and evidence that inform manufacturing forecasts, distribution needs and equitable access
- Prepare for effective data partnerships with clear research questions, appropriate governance and attention to data quality, representativeness and patient trust
- Tricha Shivas - Chief of Staff and Strategy, Foundation for Sarcoidosis Research
- Elise Hoover - Vice President, Research, Foundation for Sarcoidosis Research
Gain insights from companies at different lifecycle stages (development, peri-launch and recently launched) and contrast market access strategies to learn best practices in navigating tight payer restrictions and optimizing early payer engagement
Deep dive into strategic approaches for patient support, distribution and specialty networks to counter strict utilization management and accelerate speed-to-treatment
Hear lessons learned from recent launches to best navigate modern reimbursement negotiations, policy changes and evidence generation required for high-cost rare therapies
- Kim Burlison, MPP - Senior Director, Head US Market Access, Orchard Therapeutics
Understand how to develop internal business education around the strategic shift from early to late-stage commercialization and how individual functions may need to evolve
Learn how to address new regulatory hurdles, post-approval obligations and real-world evidence requirements that emerge as products mature in the marketplace
Explore retrospective launch lessons learned, analyzing the speed of sales growth, effective competitive strategies and how different business models play out in the same market
Discuss lifecycle management strategies and label expansion opportunities
Recognize the evolving role of patient advocacy organizations throughout the product lifecycle and strategies for maintaining meaningful partnerships as commercialization matures
- Sonit Handa, MD, MS, MBA - CEO & Founder, Biovance Consulting
- Lawrence Bressler - Vice President, Global Marketing, Mineralys Therapeutics, Inc.
- Manishi Prasad - Vice President, Market Access and Public Policy, Beam Therapeutics
Uncover what hyper-personalization truly means in rare disease and how it differs from traditional patient segmentation, addressing the multidimensional complexities across patients, caregivers and physicians
Discover strategies for designing PSPs that address the full spectrum of ongoing challenges that rare disease patients face, with a focus on adherence, persistence and long-term engagement
Explore the decision framework for determining whether your hub should be mandatory
Understand the operational infrastructure for PSPs and establish best practices in managing vendor partnerships
Learn how to navigate conversations with executive teams to position PSPs as strategic assets, balancing patient-first outcomes with commercial objectives
- Suzanne Morgan, PhD, MBA - Head, Market Access, Patient Services, Mighty Therapeutics
- Dustin Donald, PharmD, CSP - Program Director, Rare Disease, Vanderbilt Specialty Pharmacy
- Clint Divine - Senior Director, ATC Activation Strategy & Patient Services, Immix Biopharma, Inc.
Examine the paradigm shift from one disease/one treatment to competitive rare disease markets, including the evolving role of patient organizations in this landscape
Discover best practices for market and payer access strategies that facilitate speed to treatment and utilization, including patient support, distribution channels, specialty networks and external partnerships
Learn how to design patient engagement programs, generate differentiating data and build evidence stories that support product positioning in increasingly competitive environments
- Brandy Walton - Chief of Staff to CEO, Fore Biotherapeutics
- Liz Pfau - Global Neurology Marketing Lead, Amgen
- David Du - Associate Director, Market Access and Channel Strategy, Takeda
- Thomas Pangia - Director, New Business Assessment, Lupin Pharmaceuticals
Evaluate current data from USC on how to value rare disease products, and how rare drugs can be better reimbursed at higher rates
Unpack the factors shaping the evolving pricing landscape, including the impact of FDA regulatory policy, payer pressures and reaction to IRA/MFN drug price negotiations
- Learn the characterization of avenues for value-based purchasing concepts and a new approach to HTA assessment that would allow for greater flexibility and better chance at access
- Barry Liden - Director of Public Policy, Leonard D. Schaeffer Center for Health Policy & Economics
Address unique commercialization challenges for one-time curative therapies for very small patient populations
Discuss supply chain, manufacturing compliance and capacity constraints
Cover long-term patient monitoring and durability evidence generation
Highlight the access challenges along the patient journey
- Elizabeth White, PhD - Chief Operating Officer and Co-Founder, Orphan Therapeutics Accelerator, Inc.
